Our research at the ESMO Congress 2023
18 Oct 2023
This Friday marks the beginning of the ESMO Congress 2023 and our researchers from the MRC Clinical Trials Unit at UCL and our collaborators will showcase the latest work on our prostate cancer and oesophageal cancer trials.
The ESMO Congress brings together oncologists, researchers, clinicians, and professionals from around the world to discuss the latest advancements in cancer research and treatment. This year’s edition is taking place from Friday 20th to Tuesday 24th of October in Madrid, and virtually.
Details of the presentations and posters featuring the STAMPEDE trial, the RADICALS trial, the STOPCAP M1 collaboration and the OE02 trial are summarised in the tables below.
Presentations
|
Day |
Session (time) |
Session name |
Title |
Presenter |
|
Friday 20/10/23 |
4:00 PM – 4:10 PM |
Timing of Radiotherapy (RT) After Radical Prostatectomy (RP): Final Results of RADICALS RT Randomised Controlled Trial |
Noel Clarke |
|
|
Sunday 22/10/23 |
8:35 AM - 08:40 AM |
External validation of a digital pathology-based multimodal artificial intelligence (MMAI)-derived model in high-risk localized (M0)/metastatic (M1) prostate cancer (PCa) starting androgen deprivation therapy (ADT) in the docetaxel (Doc) or abiraterone (AAP) phase 3 STAMPEDE trials |
Charles T. Parker
|
|
|
Sunday 22/10/23
|
08:40 AM - 08:45 AM
|
Mini oral session - Genitourinary tumours, prostate
|
Incidence of fracture related hospitalisations in men with de novo high risk localised and metastatic hormone sensitive prostate cancer: analysis of routinely collected healthcare data from the STAMPEDE docetaxel and zoledronic acid comparisons |
Craig Jones
|
Posters
|
Day |
Poster title |
Presenter |
Poster number |
|
Sunday 22/10/23 |
Prostate radiotherapy reduces long-term risk of obstructive uropathy in metastatic hormone sensitive prostate cancer (mHSPC): results from the STAMPEDE M1|RT comparison |
Craig Jones
|
1782P
|
|
Sunday 22/10/23 |
Prostate Specific Membrane Antigen Positron Emission Tomography (PSMA PET)-directed clinical outcomes in metastatic hormone-sensitive prostate cancer (mHSPC): Implications for the STAMPEDE2 trial design |
Hoda Abdel-Aty
|
1787P
|
|
Sunday 22/10/23 |
Cardiovascular Effects of Androgen Receptor Signalling Inhibitors in the Treatment of Advanced and Metastatic Prostate Cancer: A Systematic Review and Meta-analysis of Randomised Controlled Trials |
Omar El-Taji |
1820P
|
|
Sunday 22/10/23 |
Assessing PSA Levels < 0.2 ng/ml as a Potential Surrogate for Overall Survival (OS) in men with Metastatic Hormone Sensitive Prostate Cancer (mHSPC) |
Susan Halabi |
1837P |
|
Monday 23/10/23 |
ERCC1 gene polymorphism is associated with overall survival in early oesophageal cancer: results from the phase III MRC OE02 randomised control trial |
Georgina A. Keogh |
1565P |
Further information: